Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

SA Transcripts 161.82K Followers Follow Eton Pharmaceuticals, Inc. ( ETON ) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDT Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - President, CEO & Director Judith Matthews - Chief Financial Officer & Secretary Ipek Erdogan-Trinkaus - Chief Commercial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Denis Reznik - Canaccord Genuity Corp., Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Eton Pharmaceuticals Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised this call is being recorded at the company's request. At this time, I'd like to turn the call over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. David Krempa Chief Business Officer Thank you, operator. Good afternoon, everyone, and welcome to Eton's Second Quarter 2026 Conference Call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com. Joining me on our call today, we have Sean Brynjelsen, our CEO; Ipek Trinkaus, our Chief Commercial Officer; and Judy Matthews, our Chief Financial Officer. Before we begin, I would like to remind everyone that today's remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now I will turn the call over to our CEO, Sean Brynjelsen. Sean Brynjelsen President, CEO & Director Thank you, David. Good afternoon, everyone, and thank you for joining us today. We had an exceptional second quarter with record revenue, significant margin expansion and important